The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.
The company said revenue growth during the year was driven by performance in its research reagents and screening business units.
The company, which recently signed a licensing agreement with Horizon Discovery, just raised $45 million in a Series B financing round.
The European Patent Office appeals board upheld the decision made by the EPO after its initial review in 2018.
Jennifer Doudna and Emmanuelle Charpentier are being awarded Israel's Wolf Prize in medicine for their CRISPR work, the Associated Press reports.
In PNAS this week: population genomics study on indigenous individuals in Brazil, programmable genome-editing approach, and more.
Horizon also said it will provide access to the technology to business partners for the development of more effective multi-gene knockout cell therapy programs.
Daiichi Sankyo plans to use the ERS IP to support its own R&D initiatives to address areas of unmet medical need, the company said.
Dalhousie University's Françoise Baylis discusses He Jiankui and the ethics of heritable human genome editing research in a Boston Globe op-ed.
NEB plans to expand its product lines into new areas of research including genome editing, the companies said.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.